Andre H Goy MD

PubMed

• Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
  Sunandini Sharma, Roshia Ali, Alyssa Bouska, Dylan Jochum, Meghana Kesireddy
  Nature Communications. 2025-11-05
• Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
  Tom van Meerten, Marie José Kersten, Gloria Iacoboni, Georg R Hess, Pim G N J Mutsaers
  Blood. 2025-10-29
• 2 citations
  Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies.
  Ayrton Bangolo, Behzad Amoozgar, Maryam Habibi, Elizabeth Simms, Vignesh K Nagesh
  World Journal of Gastrointestinal Pharmacology and Therapeutics. 2025-06-05

Journal Articles

• Ibrutinib for the Treatment of relapsed/refractory Mantle Cell Lymphoma: Extended 3.5-year Follow-up from a Pooled Analysis  
  Brad Kahl, Andre Goy, Haematologica
• Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
  Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
• Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration  
  Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Mil..., Am J Hematol., 1/1/2016
• Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy  
  Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen..., Ann Oncol., 1/1/2014
• A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and...  
  Casulo C, Vose JM, Ho WY, Kahl B, Brunvand M, Goy A, Kasamon Y, Cheson B, Friedberg JW, Clin Immunol., 1/1/2014
• Mantle cell lymphoma: continuously improving the odds!  
  Andre Goy, Expert Opinion on Orphan Drugs., 1/1/2013
• Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell ...  
  Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L..., Br J Haematol., 1/1/2010
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 3 PINNACLE study  
  Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI, Ann Oncol., 1/1/2009
• Mantle cell lymphoma: evolving novel options  
  Goy A, Current Oncology Rep, 1/1/2007
• Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma  
  Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M, European Journal Cancer., 1/1/2006
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma  
  Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A, Journal of Clinical Oncology, 1/1/2006
• Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with thenovel proteasome inhibitor bortezomib: a possible surrogate marker of response?  
  Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O’Connor OA., Br J Haematol, 1/1/2006
• Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relap...  
  Pro B, Fayad L, McLAughlin P, Romaguera J, Hagemeister R, Rodriguez MA, Goy A, Younes A, Leukemia Lymphoma, 1/1/2006
• Phase II Study of Proteasome Inhibitor Bortezomib (VELCADETM) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas  
  Andre Goy, Anas Younes, Peter McLaughlin, Barbara Pro, Jorge E. Romaguera, Frederick Hagemeister, Luis Fayad, Nam H Dang, Felipe Samaniego, Michael Wang, Kristine Brog..., Journal of Clinical Oncology, 1/1/2005
• Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of condit...  
  Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA,..., Bone Marrow Transplant, 1/1/2005
• Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues  
  Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL., Cancer Treat Rev., 1/1/2004
• Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic  
  Lai R, Rassidakis GZ, Medeiros LJ, Ramdas L, Goy A, Cutler C, Fujio Y, Kunisada K, Amin HM, Gilles F., Am J Pathol, 1/1/2004
• Establishment and characterization of a new mantle cell lymphoma cell line M-1  
  Goy A, Remache YK, Gu J, Stewart J, Hayes KJ, Gold D, Jiang Y, Barkoh BA, Katz R, Cabanillas F, Gilles F., Leukemia Lymphoma, 1/1/2004
• Suppressor of cytokine signaling 3 expressions in anaplastic large cell lymphoma  
  Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurger K, Remache YK, Vega F, Goy A, Gilles F, Medeiros J., Leukemia, 1/1/2004
• Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma  
  Rassidakis GZ, Goy A, Medeiros LJ, Jiang Y, Thomaides A, Remache Y, Cabanillas F, Sarris AH, Gilles F., Clinical Cancer Research, 1/1/2003
• Pentostatin in T-non-Hodgkin’s lymphomas: efficacy and effect on CD26+ T lymphocytes  
  Dang, NH, Hagemeister, FB, Duvic M, Romaguera J, Younes A, Jones D, Samuels B, Fayad L, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson..., Oncology Rep, 1/1/2003
• Muc-1 is frequently expressed in systemic and primary cutaneous anaplastic large cell lymphoma (ALCL) but rarely in other peripheral T-cell lymphoma (PTCL)  
  Rassidakis G.Z, Jones D, Medeiros LJ, Jiang Y, Thomaides A, Sarris AH, Cabanillas F, Gilles F, and Goy A, Ann Oncology, 1/1/2002
• Irinotecan in relapsed or refractory non-Hodgkin's lymphomas Indications of activity in a phase II trial  
  Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F., Oncology (Hunyingt), 1/1/2002
• T(14;18)-positive cells in peripheral blood (PB) and bone marrow (BM) of patients with follicular lymphoma (Fl) treated with Fnd+Rituxan  
  Jiang Y, Thomaides A, Rassidakis G, Sneed T, McLaughlin P, Medeiros LJ, Sarris A, Cabanillas F and Goy A., Ann Oncology, 1/1/2002
• Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma  
  Goy A, Gilles F, Remache Y, Filippa D, Portlock CS, Jhanwar SC, Zelenetz AD, Leukemia Lymphoma, 1/1/2001
• A novel gene STORP (STOmatin-Related Protein) is localized 2kb upstream of the promyelocytic gene on chromosome 15q22  
  Gilles F, Glenn M, Goy A, Remache Y, Zelenetz AD., European Journal Haematology, 1/1/2000
• High doses of intravenous recombinant erythropoietin for the treatment of anemia in myelodysplastic syndrome  
  Goy A, Belanger C, Casadevall N, Picard F, Guesnu M, Jaulmes D, Poisson D, Varet B, Br J Haematol., 1/1/1993
• High-dose recombinant human erythropoietin administered intravenously for the treatment of anemia in myelodysplastic syndromes  
  Casadevall N, Belanger C, Goy A, Varet B, Lang J, Poisson D, Acta Haematol., 1/1/1992
• Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral blood progenitor-cell mobilization regimen for transplant-eligible patients wit...  
  Moskowitz CH, Bertino, JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O’Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yaha..., Journal ClinicalOncology., 1/1/1992
• Peripheral blood stem cell collection and autografting in high-risk lymlphomas  
  Dreyfus F, Leblond V, Belanger C, Gabarre J, Sutton L, Boccaccio C, Quarre MC, Ribrag V, Goy A, Bone Marrow Transplant., 1/1/1992
• Immunotherapy of cancer using cytokinins Use and perspectives in lung oncology  
  Moro D, Goy A, Nagy-Mignotte H, Brambilla C., Rev Mal Respir., 1/1/1990
• Charcot-Marie-Tooth disease disclosed by a treatment with vincristine in familial Hodgkin’s disease  
  Geny C, Gaio JM, Mallaret M, Goy A, Reymond F, Pegourie B, Yulis J, Perret JE, Ann Med Interne (Paris), 1/1/1990
• Chemotherapy-refractory Diffuse Large B-cell Lymphoma and Indolent B-cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chime...  
  James N Kochenderfer, Mark E Dudley, Sadik H Kassim, Robert P.T. Somerville, Robert O Carpenter, Maryalice Stetler-Stevenson, James C Yang, Giao Q Phan, Marybeth S Hug..., J Clin Oncol., 1/25/2014
• High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-...  
  Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ,..., Journal of Clinical Oncology, 1/1./2006
• High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-...  
  Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ,..., J Clin Oncology, 1/1./2005
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma  
  Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NJ, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, S..., Journal of Clinical Oncology, 1/1./2005
• The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer  
  Tamir A, Gangadharan A, Balwani S, Tanaka T, Patel U, Hassan A, Benke S, Agas A, D'Agostino J, Shin D, Yoon S, Goy A, Pecora A, Suh KS, J Ovarian Res., 1/31/2016
• Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment  
  Zhao B, Chen R, O'Connor OA, Gopal AK, Ramchandren R, Goy A, Matous JV, Fasanmade AA, Manley TJ, Han TH, Br J Clin Pharmacol., 1/26/2016
• Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma  
  Schlette E.J, Medeiros L.J, Goy A, Lai R, Rassidakis G.Z., Journal of Clinical Oncology, 1/1./2004
• Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma, Erratum  
  Romaguera J, Medeiros LJ, Hagemeister F, Fayad L, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang N, Samaniego F, Brown HM, Gagneja HK, Cabanillas F., Cancer, 1/15/2003
• Join now to see all

Books/Book Chapters

• Series: Emerging Cancer Therapeutics- Lymphomas 
  Goy, A.New York, NY2012
• Bortezomib in the Treatment of Multiple Myeloma 
  Ghobrial, Irene M.; Richardson, Paul GEdition 1st,2011

Abstracts/Posters

• Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Andre Goy, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Patterns of Treatment for Newly Diagnosed and Relapsed/Refractory Peripheral T-Cell Lymphoma in the Community Setting
  Tatyana Feldman, Michael McGuire, Claudio Faria, Andre Goy, Charles Michael Farber, Kelly Choi, Jacqueline Connors, Dhakshila Paramanathan, Eric Schultz, Stuart L. Gol..., ASH Annual Meeting Abstracts, 1/1/2015
• Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL)
  Kristen M Rosenthal, Christopher R. Flowers, Andre Goy, John P. Leonard, Julie M. Vose, Erik D. Brady, Jim Mortimer, Kevin L Obholz, James O. Armitage., ASH Annual Meeting Abstracts, 1/1/2015
• Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation w...
  Jennifer N Brudno, Robert Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Dennis D. Hickstein, Juan C. Gea-Banacloche, Steven Z. Pavlet..., ASH Annual Meeting Abstracts, 1/1/2015
• Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
  Anthony Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P Skarbnik, Christina Howlett, PharmD, Jeffrey J Pu, Alison R. Sehgal,..., ASH Annual Meeting Abstracts, 1/1/2015
• BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study
  Jeremy S. Abramson, Kristie A. Blum, Ian W. Flinn, Martin Gutierrez, Andre Goy, Michael Maris, Michael Cooper, Michael O'Meara, Darrell Borger, Jennifer Mertz, Robert ..., ASH Annual Meeting Abstracts, 1/1/2015
• Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
  Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaidano, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Pawel Korolki..., ASH Annual Meeting Abstracts, 1/1/2015
• Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/...
  Asher Chanan-Khan, Paula Cramer, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Marie Sarah Dilhuydy, Andre Goy, Anthony R. Mato, Raje..., ASH Annual Meeting Abstracts, 1/1/2015
• Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)
  Ajay K Gopal, Andrew John Davies, Ian W. Flinn, Paolo Ghia, Andre Goy, Gilles A. Salles, Steve Abella, Betsy Philip, Bess Sorenson, Nina D. Wagner-Johnston., ASH Annual Meeting Abstracts, 1/1/2015
• Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3...
  Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Aleksander Pristupa, Andre ..., ASH Annual Meeting Abstracts, 1/1/2015
• Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemi...
  Paula Cramer, Asher Chanan-Khan, Graeme Fraser, Fatih Demirkan, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Andre Goy, Jiri Mayer, Mari..., ASH Annual Meeting Abstracts, 1/1/2015
• A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymp...
  Martin Gutierrez, Andre Goy, John C. Byrd, Joseph M. Flynn, Morten Sorensen, Peter Brown, Nashat Y. Gabrail, Michael Savona, Ian Flinn, Rachid C. Baz, Bijal D. Shah, R..., J Clin Oncol, 1/1/2014
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
  Nina D. Wagner-Johnston, Ajay K. Gopal, Brad S. Kahl, Sven De Vos, Stephen J. Schuster, Wojciech Jurczak, Ian Flinn, Christopher Flowers, Peter Martin, Andreas Viardot..., J Clin Oncol, 1/1/2014
• Welcome Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.
  Jeremy S. Abramson, Tatyana Feldman, Aimee Kroll, Lori S. Muffly, Eric S. Winer, Christopher Flowers, Frederick Lansigan, Chadi Nabhan, Rajneesh Nath, Jorge J. Castill..., J Clin Oncol, 1/1/2014
• Post-treatment PET scan is highly predictive of outcome (PFS and OS) in MCL pts treated with R-Hyper-CVAD in the frontline setting regardless of MIPI score.
  Anthony R. Mato, Ewelina Protomastro, Tania Zielonka, Tatyana Feldman, Harry Agress, Mary Timberg, Gabriella Gadaleta, Pritish Bhattacharyya, Alexandria Campaiola, Jak..., J Clin Oncol, 1/1/2014
• Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).
  Vijayveer Bonthapally, Marie-Helene Lafeuille, Jonathan Fortier, Mei Sheng Duh, Yvette Ng, Helgi Van De Velde, Liviu Niculescu, Esprit Ma, Andre Goy, J Clin Oncol, 1/1/2014
• Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).
  Wojciech Jurczak, Pier Luigi Zinzani, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Korolkiewicz, Mark Winderlich, ..., ASCO, 1/1/2014
• Prevalence of clinically meaningful prognostic variability in cancer: An analysis using a new taxonomy system
  Andrew Pecora, Eric V Schultz, Kelly Choi, Augie Smith, Brian LaRock, Dhakshila Paramanathan, William T. DeRosa, Andre Goy, Edward J. Licitra, David Samuel DiCapua Sie..., ASCO, 1/1/2014
• A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
  Michael Wang, Leo I. Gordon, Simon Rule, Andre Goy, Olivier Hermine, Aleksandra Rizo, Sen Hong Zhuang, Martin H. Dreyling., J Clin Oncol, 1/1/2013
• Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study.
  Michael E. Williams, Andre Goy, Rajni Sinha, Sevgi Kalayoglu Besisik, Johannes W. Drach, Rod Ramchandren, Lei Zhang, Sherri Cicero, Tommy Fu, Thomas E Witzig., J Clin Oncol, 1/1/2013
• Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
  Thomas E. Witzig, Julie Vose, Pier Luigi Zinzani, Thomas Matthew Habermann, Joseph M. Tuscano, Rajni Sinha, Michael E. Williams, Johannes W. Drach, Rod Ramchandren, Se..., J Clin Oncol, 1/1/2013
• Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM).
  Andre Goy, Vincent Ribrag, Andrea Varga, Thomas E. Witzig, Enrique M. Ocio, Luis G. Paz-Ares, Monica M. Mita, Tim Meyer, Pamela N. Munster, Amit Mahipal, Jean-Pierre D..., J Clin Oncol, 1/1/2013
• Updated interim results of an international, multicenter, phase 2 study of ibrutinib (PCI-3276) in relapsed or refractory (R/R) mantle cell lymphoma (MCL).
  Wang M, Rule S, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J, Williams ME, Barrientos JC, Chmielowska E, Radford JA, Stilgenbauer S, Dreyling M, Jedrze..., 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• Phase II Multicentre Study of Lenalidomide in Heavily Pretreated Pateitns with Relapsed/Refractory Mantle Cell Lymphoma Post-Bortezomib: MCL-001 ‘EMERGE’ STUDY
  A. Goy, M. E. Williams, R. Sinha, S. K. Besisik, J. Drach, R. Ramchandren, L. Zhang, S. Cicero, T. Fu, T. Witzig, 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• Phase I Study of the Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S with or without Rituximab (RTX) in Patients (PTS) with Relapsed or Refractory (R/R) B-cell Nonho...
  R.Advani, A. Chen, D. Lebovic, M. Brunvand, A.Goy, J. Chang, E. Hochberg, S. Yalamanchili, R. Kahn, D. Lu, A. Chai, Y. Chiu, B. Cheson., 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• Interim Results from a Phase 2 Study of PI3Kd Inhibitor Idelalisib in Patients with Relapsed Indolent Nonhodgkin Lymphoma (INHL) Refractory to Both Rituximab and an Al...
  G. A. Salles, B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jurczak, I. W. Flinn C. R. Flowers, P. Martin, A. Viardot, K. A. Blum, A. H. Goy, A. ..., 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• High Resolution Chip-Sequencing Reveals Novel Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma.
  S. Parekh, B. Kahl, A. Goy, B. Sander, R. Gascoyne, J. Brody, B. Ye, A. Melnick, 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• A Phase 3 Study of Ibrutinib in Combination with Bendamustine and Rituximab (BR) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL).
  M. Dreyling, L. Gordon, S. Rule, A. Goy, O. Hermine, S. Sun, A. Rizo, S. Zhuang, M. Wang., 12th International Conference on Malignant Lymphoma (ICML), 1/1/2013
• Single- Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma: A combined Analysis from the MCL-00, NHL- 002, AND NHL-003 Studies
  T Witzig, J Vose, P Zinzani, T Habermann, J Tuscano, R Sinha, M Williams, J Drach, R Ramchandren, S Besisik, L Zhang, S Cicero, T Fu, A Goy, European Hematology Association, 1/1/2013
• Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the Multicenter Ph...
  A Goy, R Sinha, J Vose, H Adler, S Bernstein, M Robertson, N Chen, L Zhang, S Cicero, T Fu, T Witzig., European Hematology Association, 1/1/2013
• Updated Interim Results of an International Multicenter, Phase 2 Study of Ibrutinib (PCI-32765) In Relapsed or Refractory Mantle Cell Lymphoma
  S Rule, M Wang, P Martin, R Auer, B Kahl, W Jurczak, R Advani, J Romaguera, M Williams, J Barrientos, E Chmielowska, J Radford, S Stilgenbauer, V Troung, J McGreivy, F..., European Hematology Association, 1/1/2013
• The Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI- 32765), Has Preferential Activity in the Activated B-Cell-Like (ABC) Subtype of Relapsed/Refractory (R/R)...
  S deVos, W Wilson, J Gerecitano, A Goy, V Kenkre, P Barr, K Blum, A Shustov, R Advani, N Fowler, J Vose, C Lih, M Williams, R Schmitz, Y Yang, S Pittaluga, G Wright, L..., European Hematology Association, 1/1/2013
• Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Ho...
  Ajay Gopal, MD, Brad S. Kahl, MD, Sven De Vos, MD, PhD, Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Kristie A. Blum, MD, Wojciech J. Jurczak, Ian W. Flinn, M..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Lymphoma Using Targeted DNA and RNA Sequencing.
  Kai Wang, MD PhD, Michelle Nahas, PhD, Anthony R Mato, MD, MSCE2, Amy L Donahue, MS, Jie He, PhD, Geoff A Otto, PhD, Doron Lipson, PhD, Roman Yelensky, PhD, Jeff Ross,..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bo...
  Andre Goy, MD, Michael E. Williams, MD, ScM, Sevgi Kalayoglu Besisik, MD, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jaco..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leu...
  George Nahas, DO, Arpita P Gandhi, MD, Michele L. Donato, MD, Themba Nyirenda, Ph D, David H. Vesole, MD, PhD, Andrew L Pecora, Stuart Goldberg, MD, Andre Goy, MD, Tat..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab F...
  Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Pete..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Dose Intensive Induction Followed By Allogeneic Stem Cell Transplantation More Than Doubles Progression-Free and Overall Survival In “Double-Hit” Lymphoma (DHL).
  Christina Howlett, PharmD, Andre Goy, MD, Tania Zielonka, Andrew L Pecora, MD, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L. Donato, MD, Mary Timberg, MSN, Gabri..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory...
  Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm,..., Blood (ASH Annual Meeting Abstracts), 1/1/2013
• Febrile neutropenia in hematologic malignancies: Validation of a model to select patients manageable in the outpatient setting safely
  Sarina Bains, Andre Goy, Barry Fuchs, Gabriella Gadaleta, Arun Singavi, Brenda Hurtubise, Rani Sebti, Tatyana Feldman, Stuart Goldberg, Andrew Pecora, Anthony R. Mato., J Clin Oncol, 1/1/2012
• Inotozumab Ozogamicin in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Chemotherapy or Radioimmunotherapy
  A Goy, J Leach, M Tsai, J Foran, A Forero, N Wagner-Johnston, C Ehmann, M Egyed, K Ando, K Hatake, K Tobinai, T Feldman, E Vandendries, A Volkert, SL Wang, M Ogura., European Hematology Association, 1/1/2012
• Randomized Phase II Trial Comparing Obinutuzumab (GA101) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non- Hodgkin Lymphoma: Preliminary Analysis of G...
  A Goy, F Offner, G Martinelli, D Caballero, O Gadeberg, G Gaidano, O Press, G Fine, A Chai, D Sahin, L Sehn, European Hematology Association, 1/1/2012
• The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell L...
  Wyndham H. Wilson, John F. Gerecitano, Andre Goy, Sven de Vos, Vaishalee P. Kenkre, Paul M. Barr, Kristie A. Blum, Andrei R. Shustov, Ranjana H. Advani, Jason Lih, Mic..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.
  Michael Wang, Leslie Popplewell, Robert H. Collins, Jr., Jane N. Winter, Andre Goy, Anna Robeva, Nicoletta Pirotta, Jenna Fan, Judith Klimovsky, and Owen A. O'Connor., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population.
  Anthony R Mato, Andre Goy, Kathryn Waksmundzki, Tatyana Feldman, Tania Zielonka, Ewelina A Protomastro, Coleen Bejot, Gabriella Gadaleta, Scott D Rowley, Michele L Don..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Pei-Yu Kuo, Violetta V. Leshchenko, Melissa J Fazzari, Tobias A. Gellen, Javeed Iqbal, Stefanie Baumgartner-Wennerholm, Lina Nygren, K. Stephen Suh, Andre Goy, David T..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome.
  Anthony R Mato, James Greenberg, Mary E Putt, K. Stephen Suh, Yvonne Remache, Tania Zielonka, Kathryn Waksmundzki, Ewelina A Protomastro, Susan Stives, Tatyana Feldman..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with...
  Tatyana Feldman, Anthony R Mato, Michele L. Donato, Scott D Rowley, Stuart L. Goldberg, Carolanne Carini, Marisa Valentinetti, Judith Smith, Gabriella Gadaleta, Coleen..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients.
  Anthony R Mato, Ewelina A Protomastro, Tania Zielonka, Tatyana Feldman, Scott D Rowley, Michele L Donato, Andrew L Pecora, Pritish K. Bhattacharyya, Mary Timberg, Susa..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MC...
  Andre Goy, Rajni Sinha, Michael E. Williams, Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, Michael J. Robertson, Irit Avivi, Jacob M. Rowe, Raoul..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Ce...
  Michael Wang, Simon A. Rule, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Enrique E Romaguera, Jesse McGreivy, Fong ..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
  Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J. Siegel, David D. Hurd, Kristie A. Blum, Andre Goy, Timothy S. Fenske, Amanda Cashen, Nina D. Wagner-Johnst..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Allogenic Transplantation in Lymphomas: A Focused Analysis On Aggressive Lymphomas and Factors Predictive of Outcome in a Series of 179 Pts Treated At John Theurer Can...
  Anthony R Mato, Kathryn Waksmundzki, Tania Zielonka, Ewelina A Protomastro, Theresa Amatucci, Maria Rosario, Stuart L. Goldberg, Tatyana Feldman, Scott D Rowley, Miche..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies.
  Melissa F Baker, Scott D Rowley, Stuart L. Goldberg, Anthony R Mato, Andrew L Pecora, David H. Vesole, Phyllis McKiernan, Andre Goy, and Michele L. Donato, Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.
  Andrew M. Evens, Tatyana Feldman, Aimee Kroll, Lori S. Muffly, Eric Winer, Christopher Flowers, Frederick Lansigan, Chadi Nabhan, Loretta Nastoupil, Austin Kim, Xiunin..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
  Ranjana Advani, Daniel Lebovic, Mark Brunvand, Andy I. Chen, Andre Goy, Julie E. Chang, Lauren S Maeda, William Ho, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, and Bru..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Phase 1b Study of TRU-016, an Anti-CD37 SMIP(TM) Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma
  Ajay K. Gopal, Stefano R Tarantolo, Naresh Bellam, Tatyana Feldman, Anthony R Mato, Damian J Green, Melissa Griffin, Scott Stromatt, and Andre Goy, Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Baseline Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) Expression in Circulating CD15+/CD30+ Cells Correlate with Very Poor Outcome in Hodgkin Lymphoma.
  Rajendra Gharbaran, Andre Goy, Takemi Tanaka, Jongwhan Park, Christopher J Kim, Nafis Hasan, Pritish K. Bhattacharyya, Anthony R Mato, Tatyana Feldman, Andrew L Pecora..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT.
  David Halverson, Miriam E. Mossoba, Seth M. Steinberg, Bazetta blacklock-Schuver, Frances T. Hakim, Roger Kurlander, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hard..., Blood (ASH Annual Meeting Abstracts), 1/1/2012
• Phase I-II Study of Bortezomib in Combination with RHCVAD and R-Methotrexate/Cytarabine (R-MA) in Untreated Mantle Cell Lymphoma (MCL)
  J. E. Romaguera, M. Wang, F. Hagemeister, P. Weaver, K. Hartig, M. Fanale, L. E. Fayad, T. Feldman, N. Fowler, R. Orlowski, J. Smith, P. Ford, M. Ekaney, L. W. Kwak, A..., (International Conference on Malignant Lymphoma), 1/1/2011
• Inotuzumab Ozogamicin (INO, CMC-544) in Pts with Indolent B-Cell NHL Refractory to Rituximab (R), R Plus Chemotherapy, or Radioimmunotherapy (RIT)
  A. Goy, J. Leach, W. C. Ehman3,M. Egyed, K. Ando, K. Hatake, K. Tobinai, T. Feldman, S. Hua, A. Volkert, E. Vandendries, M. Ogura., International Conference on Malignant Lymphoma, 1/1/2011
• The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous ...
  T. Feldman, A. R. Mato, T. Zielonka, S. D. Rowley, S. Goldberg, M. Donato, D. S. D. Siegel, K. Facchin, A. Campaiola, D. H. Vesole, C. Bejot, S. Stives, M. Curtin, M. ..., J Clin Oncol, 1/1/2011
• A new predictive model based on age, pretreatment LDH, and post-therapy PET-CT in patients with MCL treated with dose-intensive strategies.
  A. R. Mato, T. Feldman, T. Zielonka, S. Goldberg, S. D. Rowley, M. Donato, D. S. D. Siegel, D. H. Vesole, A. Campaiola, K. Facchin, S. Stives, C. Bejot, M. Curtin, M. ..., J Clin Oncol, 1/1/2011
• A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chro...
  F. T. Awan, J. M. Pagel, A. Goy, R. M. Rifkin, B. J. Poiesz, A. R. Mato, S. C. Stromatt, J. C. Byrd, U. Jaeger., J Clin Oncol, 1/1/2011
• Laurie H. Sehn, MD, MPH, Andre Goy, MD, Fritz C. Offner, MD, PhD , Giovanni Martinelli, MD, Jonathan Friedberg, MD, Susan F. Lasserre, MSc, Gregg Fine, MD and Oliver W..., (American Society of Hematology Annual Meeting), 1/1/2011
• The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Ph...
  Luhua Wang, MD, Peter Martin, MD, Kristie A. Blum, MD, Brad S. Kahl, MD, Lauren S. Maeda, MD, Ranjana H. Advani, MD, Michael E. Williams, MD, Simon Rule, MD, Sara Rodr..., American Society of Hematology Annual Meeting, 1/1/2011
• High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma
  Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Netha Ulahannan, MS, Elana Braunschweig, Yiting Yu, PhD, K. Stephen Suh, PhD, Marc A. Weniger, PhD, Andre Goy, MD, Wyndham..., American Society of Hematology Annual Meeting, 1/1/2011
• High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma
  Pei-Yu Kuo, MS, Violetta V. Leshchenko, PhD, Tobias A. Gellen, Netha Ulahannan, MS, Paul Zumbo, BA, BS, Christopher E. Mason, PhD, Wyndham H. Wilson, MD, PhD, Adrian W..., American Society of Hematology Annual Meeting, 1/1/2011
• Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)
  David J. Straus, MD, Madeleine Duvic, MD, Steven M. Horwitz, MD, Kenneth B. Hymes, MD, Andre Goy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Tatyana Feldman, MD, Bre..., American Society of Hematology Annual Meeting, 1/1/2011
• Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237) – An Investigational Aurora A Kinase Inhibitor – in Patients with Advanced Hematologic Malignancies
  Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee,..., American Society of Hematology Annual Meeting, 1/1/2011
• Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy
  Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, ..., American Society of Hematology Annual Meeting, 1/1/2011
• A Decade of Stem Cell Transplantation in Lymphoma: Single Center Experience and Outcome of 938 Consecutive Allogeneic and Autologous Hematopoietic Stem Cell Transplant...
  Anthony R Mato, MD, Andrew L Pecora, MD, Scott D Rowley, MD, Michele L Donato, MD, Stuart L. Goldberg, MD, Tatyana Feldman, MD, David H. Vesole, MD, PhD, Tania Zielonk..., American Society of Hematology Annual Meeting, 1/1/2011
• Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience
  Michele L. Donato, MD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD , Barbara Adler-Brecher, Eiswarya Chichili, MD, Andrew L Pecora, MD*, Phyllis McKiernan, APN,..., American Society of Hematology Annual Meeting, 1/1/2011
• Response of relapsed/ refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituxi...
  F. J. Hernandez-Ilizaliturri, G. Deeb, P. L. Zinzani, S. A. Pileri, F. Malik, W. R. Macon, T. E. Witzig, A. Goy, M. S. Czuczman., Journal of Clinical Oncology, 1/1/2010
• The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with ...
  A. R. Mato, T. Zielonka, T. Feldman, P. Bhattacharyya, C. Bejot, N. George, S. Stives, S. Goldberg, A. Pecora, A. Goy., Journal of Clinical Oncology, 1/1/2010
• Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma.
  J. G. E. Manoukian, F. B. Hagemeister, P. McLaughlin, L. Fayad, F. Samaniego, A. Goy, J. E. Romaguera, B. Pro, F. Cabanillas, M. A. Rodriguez., Journal of Clinical Oncology, 1/1/2010
• Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell...
  T. Feldman, A. R. Mato, T. Zielonka, A. Masood, S. Goldberg, S. D. Rowley, M. Donato, D. S. Siegel, A. Pecora, A. Goy, Journal of Clinical Oncology, 1/1/2010
• Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma.
  D. J. Straus, M. Duvic, S. M. Horwitz, K. B. Hymes, A. Goy, F. J. Hernandez-Ilizaliturri, T. Feldman, B. Wegner, P. Myskowski., Journal of Clinical Oncology, 1/1/2010
• Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.
  F. M. Foss, N. N. Sjak-Shie, A. Goy, R. Advani, E. D. Jacobsen, Journal of Clinical Oncology, 1/1/2010
• Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment after Low-Intensity Chemotherapy
  Daniel H. Fowler, Miriam E. Mossoba, Bazetta Blacklock Schuver, Paula Layton, Frances T Hakim, Roger Kurlander, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, St..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF).
  Francine M Foss, Steven M Horwitz, Lauren Pinter-Brown, Andre Goy, M, Barbara Pro, Bertrand Coiffier, Leslie Popplewell, Kerry Joanne Savage, Andrei Shustov, Jasmine M..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens
  Andre Goy, Barbara Pro,Kerry Joanne Savage, MD, Nancy L. Bartlett, Mary Jo Lechowicz, Eric D Jacobsen, Faith Young, Michael Crump, Hossein Borghaei, Brian Link, Steven..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.
  Swaminathan Padmanabhan, Thomas C. Shea, Julie M. Vose, Craig B. Reeder, Jesus G Berdeja, Kevin T. McDonagh, Andre Goy, Kevin R Kelly, Xiaofei Zhou, Hua Liu, Howard Fi..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab in Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
  Nina Wagner-Johnston, Andre Goy, Tatyana Feldman, Yeow Tee Goh, Cheolwon Suh, John William Sweetenham, Christine Powell, Sharon T. Sullivan, Erik R. Vandendries, Chris..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• R-HCVAD/R-MTX-Arac (R-HCVAD) Overcomes Risk Features Associated with Inferior Outcomes In the Treatment of Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma.
  Anthony R Mato, Tatyana Feldman, Tania Zielonka, Pritish K. Bhattacharyya, Alexandria Campaiola, Rina P Shah, Maria Rosario, Coleen Bejot, Susan Stives, Mary Curtin, R..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells.
  Carlos Caicedo-Carvajal, Qing Liu, Andre Goy, Andrew L Pecora, Anthony R Mato,Tatyana Feldman, K. Stephen Suh., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Prelimin...
  Andre Goy, Joseph Leach, W. Christopher Ehmann, Kiyoshi Ando, Kiyohiko Hatake, Kensei Tobinai, Tatyana Feldman, Steven Hua, Angela DG Volkert, Erik R. Vandendries,Mich..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.
  Vicki A. Morrison, Richard I Fisher, Andre Goy, Sven de Vos, Steven H. Bernstein, Anthony Boral, Rachel Neuwirt., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• Post-Treatment (not interim) PET-CT Scan Status Is Highly Predictive of Outcome In Mantle Cell Lymphoma Treated with R-Hypercvad or ASCT.
  Anthony R Mato, MD, Tania Zielonka, Tatyana Feldman, MD, Jakub Svoboda, MD, Harry Agress, MD, David Panush, MD, Mitchell Miller, MD, Patrick Toth, MD, Elise A Chong, B..., Blood (American Society of Hematology Annual Meeting), 1/1/2010
• A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
  Todd A Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J Siegel, Amanda F Cashen, Kristie A Blum, Timothy S. Fenske, David D Hurd, Andre Goy, John F. DiPersio, and N..., Blood (American Society of Hematology Annual Meeting), 1/1/2009
• A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and...
  Jonathan W. Friedberg, Julie M. Vose, Brad S Kahl, Mark W. Brunvand, Andre Goy, Yvette L. Kasamon, Bart Burington, Jing Li, William Ho, and Bruce D. Cheson., Blood (American Society of Hematology Annual Meeting), 1/1/2009
• Combination Melphalan and Bortezomib Conditioning with Autologous Hematopoietic Stem Cell Support in Patients with Advanced Multiple Myeloma. A Phase I/II Study
  Scott D. Rowley, David Siegel, Michele L. Donato, Andrew L. Pecora, Tatyana Feldman, Stuart Goldberg, Andre Goy, and Aisha Masood, Blood (American Society of Hematology Annual Meeting), 1/1/2009
• Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).
  Kerry J. Savage, Andrei R. Shustov, Andre Goy, Steven M. Horwitz, Barbara Pro, Molly Patterson, Steven Fruchtman, and Owen A O'Connor, Blood (American Society of Hematology Annual Meeting), 1/1/2009
• Join now to see all

Lectures

• How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Updates on Lymphoma and Treatment Options 
  Hackensack, NJ - 1/1/2016
• MCL: Changing Paradigm? 
  New York - 1/1/2016
• Targeted Therapies in Early, Mid, and Late Development- Building on R-CHOP by Tackling the Lymphoma Microenvironment 
  1/1/2014
• Relapsed/Refractory Status: Old/New Agents- Lenalidomide 
  Bologna, Italy - 1/1/2014
• Advanced-Stage DLBCL 
  New York, NY - 1/1/2013
• Stem Cell Transplantation in Indolent Lymphoma 
  New York, NY - 1/1/2013
• IMIDs in Lymphoma 
  New York, NY - 1/1/2013
• Novel Agents for Follicular and Mantle Cell Lymphomas 
  New York, NY - 1/1/2013
• Novel Agents for Follicular and Mantle-Cell Lymphomas 
  New York, NY - 1/1/2013
• Debate: “What is the best upfront treatment for mantle-cell lymphoma in a 60 year old patient? Chemoimmunotherapy followed by maintenance” 
  New York, NY - 1/1/2013
• Other Novel Targeted Agents of Clinical Interest for NHL and/or CLL and Their Potential Importance 
  Washington, D.C. - 1/1/2013
• Updates in Relapsed Mantle Cell Lymphoma 
  NJ - 1/1/2013
• New Treatment Option in Previously Treated Mantle Cell Lymphoma 
  NJ - 1/1/2013
• Celgene: IMiDs in Mantle Cell Lymphoma 
  Munich, Germany - 1/1/2013
• Inotuzumab Ozogamicin 
  Bologna, Italy - 1/1/2013
• New Drugs in Hematology 
  Bologna, Italy - 1/1/2013
• Novel Approaches in Mantle Cell Lymphoma 
  Switzerland - 1/1/2013
• Debate: Should an asymptomatic patient with low tumor burden Mantle Cell Lymphoma be observed or receive immediate treatment? Immediate treatment is the best option. 
  New York, NY - 1/1/2012
• Elderly patients with Mantle Cell Lymphoma 
  New York, NY - 1/1/2012
• How to treat large cell lymphoma in the very elderly, including EB+ disease 
  New York, NY - 1/1/2012
• Expert Insight in NHL: Current Critical Issues and Future Research Priorities 
  New York, NY - 1/1/2012
• Therapeutic options on mantle cell lymphoma on first line and at relapse 
  Cancun, Mexico - 1/1/2012
• Case Study: Progress in the treatment of mantle cell lymphoma: applying the results of the most current clinical trials for both newly diagnosed patients and relapsed ... 
  1/1/2011
• Optimizing Therapeutic Choices for Frontline Treatment and Beyond in Patients with Indolent Non-Hodgkin Lymphoma 
  University of Southern California, CA - 1/1/2011
• Update on Lymphomas 
  UMDNJ - 1/1/2011
• Advances in the Treatment of Relapsed Mantle Cell Lymphoma 
  1/1/2011
• Lymphomas: Improving Patient Care 
  1/1/2011
• Frequently Asked Questions in Lymphoma: Answers from the Experts 
  1/1/2011
• Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma: Evolving Treatment Paradigms in Diffused Large B-Cell Lymphoma 
  1/1/2011
• Follicular Lymphoma 
  1/1/2011
• Inotuzumab Ozogamicin (INO, CMC-544) in patients with Indolent B Cell NHL Refractory to Rituximab, (R) Plus Chemotherapy, or Radioimmunotherapy (RIT) 
  Lugano, Switzerland - 1/1/2011
• Treatment of Relapsed Mantle Cell Lymphoma- Where is it going? 
  Temple Comprehensive Cancer Center - 1/1/2010
• Updates in Patient Clinical Outcomes in Relapsed Mantle Cell Lymphoma 
  Chevy Chase, MD, 2010; Bethesda, MD, 2010 - 1/1/2010
• Clinical Advances and Research Directions in Hematologic Malignancies 
  1/1/2010
• Multidisciplinary Approaches for the Diagnosis and Optimal Treatment of Mantle Cell Lymphoma 
  1/1/2010
• Progress in the treatment of newly diagnosed patients with mantle cell lymphoma: applying results of the newest clinical trials 
  Arlington, VA - 1/1/2010
• Diagnosis and Optimal Treatment of Mantle Cell Lymphoma 
  Torrington, CT - 1/1/2010
• Overview of Protein Metabolism and Disease 
  1/1/2010
• Targeting the Ubiquitin-Proteasome Pathway 
  1/1/2010
• Improving Outcomes in Indolent Non-Hodgkin Lymphoma: Applying Evidence to Practice 
  University of Nebraska - 1/1/2010
• Indolent Lymphomas 
  1/1/2010
• Mantle Cell Lymphoma 
  1/1/2010
• Biomarkers in Non-Hodgkin Lymphoma 
  1/1/2010
• Meet the Expert Session on Mantle Cell Lymphoma 
  1/1/2010
• DLBCL: Emerging Agents 
  New York - 1/1/2010
• Should Mantle Cell Lymphoma be treated aggressively from the onset 
  NY, N.Y. - 1/1/2009
• Mantle Cell Lymphoma International Consortium 
  New Orleans, LA - 1/1/2009
• Broader Topic of Proteasome Inhibition in Lymphoma 
  Shanghai, China - 1/1/2009
• Relapsed Mantle Cell Lymphoma launch Symposium 
  Kunming, China - 1/1/2009
• Proteasome Inhibition in Lymphoma + Relapsed MCL/Pinnacle 
  Singapore - 1/1/2009
• Proteasome Inhibitors for Lymphomas: where do we stand? 
  Brussels - 1/1/2009
• Les Nouveaux développements thérapeutiques des lymphomes 
  Deuxièmes Universités Janssen-Cilag d’Hématologie, Chantilly, France - 1/1/2009
• Therapeutic Advances: the molecules for hope Side effects of newly developed targeted therapies: What you need to know 
  Vienna, Austria - 1/1/2009
• Hematological Oncology Overview 
  Roswell Park Cancer Center - 1/1/2008
• New Developments in the Treatment of Lymphoma 
  Baltimore, MD - 1/1/2008
• Management of Aggressive Lymphoma 
  White Plains, N.Y. - 1/1/2008
• Clinical Issues and Future Directions in Hematological Malignancies: Non Hodgkin in Lymphoma Presentation 
  Miami, FL - 1/1/2008
• State of the Art Treatment of Mantle Cell Lymphoma 
  Boston, MA - 1/1/2008
• Obatoclax Bortezomib Trial in Lymphoma 
  1/1/2008
• Session: New and Conventional Therapeutic Approaches in Bortezomib 
  Turin, Italy - 1/1/2008
• New Therapeutic Strategies in Mantle Cell Lymphoma 
  Whistler, BC - 1/1/2008
• Mantle Cell Lymphoma Introduction and Treatment Update 
  Margarita Island, Venezuela - 1/1/2008
• New insights in the management of Mantle Cell Lymphoma 
  Geneva, Switzerland, University Hospital Geneva CH - 1/1/2008
• New insights in the management of MCL 
  Lausanne, Switzerland, University Hospital Lausanne CH - 1/1/2008
• Evolving Options in Mantle Cell Lymphoma 
  Lugano, Switzerland - 1/1/2008
• New concepts in NHL trials with bortezomib and pan Bcl-2 inhibitors 
  San Francisco, CA - 1/1/2007
• Optimizing Therapy for CD20-Expressing B-Cell Malignancies 
  Huntington, NY - 1/1/2007
• Mantle Cell Lymphoma: An Update for Clinicians 
  Tampa, FL - 1/1/2007
• Multiple Myeloma, Lymphoma and MDS 
  Saint Vincent Cancer Center - 1/1/2007
• Prognostic markers in Mantle Cell Lymphoma 
  Shreveport, LA - 1/1/2007
• Promising Directions in Mantle Cell Lymphoma, and Waldenstrom’s Macroglobulinemia, Treatment of Lymphoproliferative Malignancies: Hawaii 
  1/1/2007
• Novel Cytotoxic and Targeted Agents in Lymphoproliferative Disorders 
  1/1/2007
• Proteasome Inhibitors 
  1/1/2007
• Novel Therapeutics Development in Lymphoma 
  Huntsman Cancer Center, Salt Lake City, Utah - 1/1/2007
• Potential for proteasome inhibitors in NHL 
  1/1/2007
• Course High Grade Lymphomas 
  Imperial College - 1/1/2007
• Update on HyperCVAD in MCL and mTORs in MCL 
  Las Cobras, Puerto Rico - 1/1/2007
• An Oral Presentation on the results of PINNACLE trial 
  1/1/2006
• Proteasome Inhibitors in Lymphoma 
  1/1/2006
• Evolving Treatment Options in Follicular Lymphoma 
  1/1/2006
• Management of MCL 
  Whistler, Canada - 1/1/2006
• Bortezomib alone and in combination for Indolent Lymphomas 
  Barcelona, Spain - 1/1/2006
• Gela 
  Dijon, France - 1/1/2006
• Proteasome Inhibitors as Single Agent and in Combination in Lymphoma 
  Barcelona - 1/1/2006
• mTORs inhibitors in lymphoma 
  Barcelona - 1/1/2006
• Impact of Genomics on Cancer management 
  Scientific Symposium - 1/1/2006
• Update on Hematological Malignancies 
  Boston, MA - 1/1/2005
• New Directions in Lymphoma 
  Philadelphia, PA - 1/1/2005
• Rituximab and Bortezomib in Non Hodgkin Lymphoma 
  1/1/2005
• Proteasome inhibition in Lymphoma 
  Maui, Hawaii - 1/1/2005
• Update on Novel Approaches in Non Hodgkin Lymphoma 
  Norfolk, VA - 1/1/2005
• New perspectives in Mantle Cell Lymphoma 
  1/1/2005
• Rationale for combination using bortezomib with chemotherapy in lymphoma 
  Whistler, BC, Canada - 1/1/2005
• Follicular Lymphoma Next Steps? 
  1/1/2005
• Join now to see all

Other

• Complications of Monoclonal Antibodies in Hematological Malignancies 
  New Book Infectious Diseases in Immunocompromised Host
  1/1/2009
• Diagnosis and Management of Other Lymphoproliferative Disorders. 
  Goy A H, Amin HM, Cabanillas F, Medeiros LJ, Non-Hodgkin’s Lymphomas
  1/1/2004